Capricor Therapeutics (CAPR) provided regulatory updates related to its Biologics License Application, BLA, for Deramiocel, the Company’s lead cell therapy candidate for the treatment of Duchenne Muscular Dystrophy, DMD,-associated cardiomyopathy. As part of the FDA’s ongoing review, the Company has been informed that an Advisory Committee meeting is not indicated at this time. The BLA remains under Priority Review with a Prescription Drug User Fee Act, PDUFA, target action date of August 31, 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Roth says ‘excessive’ Capricor selloff due to ‘investor overreaction’
- Capricor selloff brings buying opportunity, says H.C. Wainwright
- Capricor Therapeutics price target lowered to $22 from $43 at Oppenheimer
- Capricor Therapeutics participates in a conference call with Cantor Fitzgerald
- JonesResearch says CRL would not be end for Capricor’s deramiocel